PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 14, 2026Intestinal Research0 citationsOpen Access

Efficacy and safety of subcutaneous guselkumab in East Asian participants with moderately to severely active Crohn’s disease: subgroup analysis of the Phase 3 GRAVITI study

View Full Paper
WLWenjia LiuBeijing Proteome Research CenterHGHong GuoChongqing UniversityTKTae Oh KimInje University Haeundae Paik Hospital

Key Points

  • The aim is to evaluate the efficacy and safety of subcutaneous guselkumab in East Asian participants with Crohn's disease.
  • Subgroup analysis from the Phase 3 GRAVITI study
  • Focused on moderately to severely active Crohn’s disease
  • Compared results with the global study outcomes
  • Efficacy and safety findings align with global study results
  • Subcutaneous guselkumab demonstrated effectiveness for Crohn’s disease
  • Safety profile found consistent across populations

Abstract

Efficacy and safety results of SC guselkumab in East Asian participants with moderately to severely active CD reflect findings from the global study.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/699011032ccff479cfe57646https://doi.org/10.5217/ir.2025.00107
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An Update on the Epidemiology of Inflammatory Bowel Disease in Asia2008 · 543 citations
  2. 2Clinical Experiences in Primary and Secondary Immunodeficiencies and Immune-Mediated Conditions using Gammanorm ®2016 · 10 citations
  3. 3Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial2020 · 250 citations
  4. 4Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases2020 · 23 citations
  5. 5Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective2021 · 51 citations